A Complete Response to Immune Checkpoint Therapy in A Treatment Refractory Patient with Metastatic Pancreatic Cancer and Mismatch Repair Deficiency
Pancreatic cancer remains a difficult to treat malignancy. Advanced application of targeted chemotherapeutics has extended survival but has not resulted in cure. Recently, the application of immunotherapy has shown promise in cancers that harbour mismatch repair deficiencies and micro-satellite instability. Here, we show a metastatic pancreatic cancer with a mismatch repair deficiency respond dramatically to PD-1 inhibitor therapy.